Faes Farma, S.A.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Madrid Spain (1933)
Status: No NME R&D (1933)

Organization Overview

First Clinical Trial
2003
NCT01108783
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

FAES Farma | Faes Farma, S.A.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Coronavirus Infections (Phase 2)

Hypersensitivity (Phase 2)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Syndrome (Phase 2)

Urticaria (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 12